Table 1 Drug sensitivity of lymphoid cell models overexpressing UGT2B17 compared to control cells.

From: UGT2B17 modifies drug response in chronic lymphocytic leukaemia

 

Fludarabine

Ibrutinib

Idelalisib

Venetoclax

Chlorambucil

Bendamustine

MEC1 cells

CTRL IC50 (µM)

29.27

0.99

1.73

2.22

7.99

60.09

2B17 IC50 (µM)

58.82

4.13

7.40

4.16

12.35

76.05

P

<0.001

<0.001

0.014

0.025

<0.001

0.094

Fold over control

2.01

4.17

4.28

1.87

1.55

1.27

JVM2 cells

CTRL IC50 (µM)

9.08

3.64

1.79

4.06

10.38

54.24

2B17 IC50 (µM)

15.05

8.95

2.95

2.94

8.64

62.78

P

<0.001

0.013

0.588

0.100

0.278

0.233

Fold over control

1.66

2.46

1.65

0.72

0.83

1.16

  1. Half-maximal inhibitory concentrations (IC50) are shown for cells overexpressing UGT2B17 (2B17) or controls (CTRL). Cell viability was tested by a colorimetric (MTS) assays with at least seven drug concentrations, ranging from 1 nM to 100 µM (distinct range for each drug) to establish the IC50. P values below 0.05 were considered statistically significant (in bold). Assays were replicated at least three times in triplicates. Similar results were obtained using AnnexinV/PI labelling (data not shown).
Back to article page